Fieldview Capital Management LLC Takes $453,000 Position in DexCom, Inc. $DXCM

Fieldview Capital Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 6,822 shares of the medical device company’s stock, valued at approximately $453,000.

Several other hedge funds have also made changes to their positions in DXCM. CVA Family Office LLC grew its stake in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after buying an additional 147 shares during the period. MCF Advisors LLC purchased a new position in shares of DexCom during the 4th quarter worth approximately $32,000. ORG Partners LLC boosted its position in shares of DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after purchasing an additional 281 shares during the period. Spire Wealth Management boosted its position in shares of DexCom by 113.8% during the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after purchasing an additional 305 shares during the period. Finally, Aventura Private Wealth LLC purchased a new position in shares of DexCom during the 4th quarter worth approximately $43,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In other news, EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $74.13, for a total value of $364,052.43. Following the sale, the executive vice president directly owned 95,450 shares in the company, valued at approximately $7,075,708.50. This trade represents a 4.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00. Following the completion of the sale, the executive vice president owned 109,504 shares in the company, valued at $6,560,384.64. The trade was a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 40,994 shares of company stock valued at $2,919,022 over the last quarter. Company insiders own 0.28% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DXCM. Barclays reaffirmed an “underweight” rating and set a $64.00 price objective (down from $67.00) on shares of DexCom in a research report on Monday, May 18th. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 10th. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a research report on Tuesday, March 24th. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research report on Friday, May 1st. Finally, Benchmark began coverage on shares of DexCom in a research report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average target price of $84.83.

DexCom Stock Performance

Shares of DXCM stock opened at $74.22 on Tuesday. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The stock has a market capitalization of $28.64 billion, a PE ratio of 31.72, a P/E/G ratio of 1.18 and a beta of 1.45. The firm has a 50 day moving average of $66.37 and a two-hundred day moving average of $67.68.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same quarter last year, the company posted $0.32 EPS. The firm’s revenue was up 15.0% compared to the same quarter last year. On average, research analysts predict that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.